Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
You may also be interested in...
Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.
Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.
Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.